ZZU-iPS-SCA3-003

General

Cell Line

hPSCreg name ZZUi026-A
Cite as:
ZZUi026-A (RRID:CVCL_A3ZM)
Alternative name(s)
ZZU-iPS-SCA3-003
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UKBi003-A
(iLB-MJD1-32m-r9, LB-32-r9)
Donor's gene variants:
ATXN3, ATXN3
Donor diseases:
Machado-Joseph disease
UKBi008-A
(iLB-MJD4-34m-r1, LB-34-1)
Donor's gene variants:
ATXN3, ATXN3
Donor diseases:
Machado-Joseph disease
UKBi001-B
Donor's gene variants:
ATXN3
Donor diseases:
Machado-Joseph disease
ZZUi014-A
(ZZU-iPS-SCA3-002)
Donor diseases:
Spinocerebellar ataxia type 3
UKBi007-A
(LB-33-5, iLB-MJD3-33f-r5)
Donor's gene variants:
ATXN3, ATXN3
Donor diseases:
Machado-Joseph disease
ZZUi004-A
(ZZU-iPS-SCA3-001)
Donor diseases:
Spinocerebellar ataxia type 3
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
UTSWi001-A
(FA1)
Donor diseases:
Friedreich Ataxia
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
HDZi003-A
(hiPSC NP0038)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
FRIMOi004-A
(STGD2_ FiPS4F1.7)
Donor diseases:
Stargardt Disease
VUi011-A
(SCZ 3.5)
Donor diseases:
Schizophrenia
STBCi320-A
(SFC031-03-03)
Donor diseases:
Parkinson disease
STBCi295-B
(SFC847-03-08)
Donor diseases:
Parkinson disease
LCSBi013-A
(GL2)
Donor diseases:
Parkinson Disease
CRICKi005-A
(iFCI004)
Donor diseases:
spinal muscular atrophy
CRICKi006-A
(iFCI005)
Donor diseases:
spinal muscular atrophy
DANi002-C
(GBA-002-C3)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
DANi003-H
(GBA-003-C8)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
DANi005-A
(LRRK2-GBA-005-C1)
Donor's gene variants:
GBA, LRRK2
Donor diseases:
Parkinson Disease
ZZUi012-A
(ZZU-iPS-PFBC-SLC20A2-001)
Donor diseases:
Bilateral striopallidodentate calcinosis
LCPHi003-A
Donor's gene variants:
LRP10
Donor diseases:
Parkinson Disease
DHMi004-A
(HOS_1460)
Donor diseases:
Holt-Oram Syndrome
UMi036-A
(ND34263)
Donor diseases:
Parkinson Disease
ZZUi013-A
(ZZU-iPS-AD-MEOX2-001)
Donor diseases:
obsolete_Alzheimer's disease
UPITTi004-A
(CN090 C5A5J2)
Donor diseases:
Sickle cell anemia
UPITTi004-B
(CN090 C1B5B5)
Donor diseases:
Sickle cell anemia
ZZUi027-A
(ZZU-iPS-PD-RAB39b-002)
Donor diseases:
Parkinson Disease
LCSBi001-A
(VPS35 1_2)
Donor diseases:
obsolete_Parkinson's disease
FDHSi002-A
(FDITBRi002-A)
Donor diseases:
Parkinson Disease
UCSCi001-A
(SII-1802)
Donor diseases:
Amyotrophic Lateral Sclerosis
Last update 22nd March 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator The first affiliated hospital (ZZU)
Owner The first affiliated hospital (ZZU)
Derivation country China

External Databases

BioSamples SAMEA7976386
Cellosaurus CVCL_A3ZM
Wikidata Q105511892

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Ethnicity Han

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation.
Synonyms
  • SCA3
  • Machado-Joseph Disease
  • Spinocerebellar Ataxia Type 3

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA7976387

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? No
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Medical Research Ethics Committee of The First Affiliated Hospital of Zhengzhou University
Approval number 2016-007
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Medical Research Ethics Committee of The First Affiliated Hospital of Zhengzhou University
Approval number 2016-007
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: Medical Research Ethics Committee of The First Affiliated Hospital of Zhengzhou University
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? Yes
Further constraints on use This material and derived cells can't be used for commercial purpose or clinical transplant.
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? STEMCELL Technologies Inc
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? Yes
Constraints for use or distribution All the resources will be only used for non-commercial scientific research, instead of any other purposes.

hIPSC Derivation

General

Source cell type

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
Yes
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
Yes
Derived under GMP?
Yes
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 95 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)